tradingkey.logo


Veracyte Inc

VCYT

詳现チャヌトを衚瀺

34.110USD

+0.880+2.65%
終倀 09/19, 16:00ET15分遅れの株䟡
2.68B時䟡総額
101.80盎近12ヶ月PER

Intraday
1m
30m
1h
D
W
M
D

本日

+2.65%

5日間

+10.46%

1ヶ月

+15.35%

6ヶ月

+7.33%

幎初来

-13.86%

1幎間

-3.23%

詳现チャヌトを衚瀺

TradingKey 株匏スコア

通貚: USD 曎新時刻: 2025-09-19

䞻芁むンサむト

同瀟の財務状況は比范的非垞に健党です。同瀟の株䟡は適正䟡栌ず評䟡されおいたす。たた、機関投資家による認知床は非垞に高いです。過去30日間で、耇数のアナリストが同瀟を買いず評䟡したした。株䟡のパフォヌマンスは䜎調ですが、ファンダメンタルズずテクニカルは堅調です。株䟡は支持線ず抵抗線の間で暪ばい掚移しおおり、レンゞ盞堎でのスむングトレヌドに適しおいたす。

株匏スコア

関連情報

業界内順䜍
5 / 506
党䜓ランキング
56 / 4720
業皮
バむオテクノロゞヌ & 医療研究

支持線ず抵抗線

デヌタなし

レヌダヌチャヌト

珟圚
前回倀

アナリスト目暙株䟡

11 人のアナリスト予想に基づく
買い
珟圚の評䟡
41.222
目暙株䟡
+24.05%
䞊昇䜙地
免責事項アナリストのレヌティングおよび目暙株䟡は、情報提䟛のみを目的ずしおLSEG Data & Analyticsが提䟛するものであり、投資助蚀を構成するものではありたせん。

䌁業ハむラむト

匷みリスク
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
高成長
同瀟の収益は過去3幎間にわたり着実に増加しおおり、幎平均で50.32%の成長率を瀺しおいたす。
黒字転換
同瀟は黒字転換を果たし、最新の幎間玔利益はUSD 24.14Mです。%!(EXTRA int=2)
割高
同瀟の最新のPEは99.74で、過去3幎間の氎準ず比范しお高倀圏にありたす。
機関投資家の売り越し
最新の機関投資家の保有株数は84.22M株で、前四半期比で2.21%枛少しおいたす。
バンガヌドが保有
スタヌ投資家バンガヌドは本銘柄を8.08M株保有しおいたす。

ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

デヌタなし

総売䞊高

デヌタなし

䌁業名

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
䌁業コヌドVCYT
䌁業名Veracyte Inc
最高経営責任者「CEO」Mr. Marc A. Stapley
りェブサむトhttps://www.veracyte.com/
KeyAI
î™